free contador

Immunotherapy Drugs Market worth $ 274.6 billion by 2025 – Exclusive Report by MarketsandMarkets™

Comentarios · 53 Vistas

The global immunotherapy drugs market is projected to reach USD 274.6 billion by 2025 from USD 163.0 billion in 2020, at a CAGR of 11.0 % during the forecast period.

Immunotherapy Drugs Marketby Type (Monoclonal Antibodies, Check Point Inhibitors, Interferons, and Interleukins), Therapy Area (Cancer, Autoimmune diseases Inflammatory, Infectious Diseases), End User (Hospitals, Clinics ) - Global Forecast to 2025", is projected to reach USD 274.6 billion by 2025 from USD 163.0 billion in 2020, at a CAGR of 11.0% during the forecast period. The growth of this market is majorly attributed to the increasing adoption of immunotherapy drugs over conventional treatment regimens, the rising prevalence of cancer and autoimmune infectious diseases, increasing demand for monoclonal antibodies and biosimilars, and fast track approvals from regulatory bodies.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137717755

Browse in-depth TOC on "Immunotherapy Drugs Market”

114 – Tables

34 – Figures

176 – Pages

Cancer commanded the largest share of the immunotherapy drugs market, by therapeutic area, in 2019.

Based on therapeutic area, the immunotherapy drugs market has been segmented into cancer, autoimmune and inflammatory diseases, infectious diseases, and other therapeutic areas. Cancer accounted for the largest share of the immunotherapy drugs market in 2019. Factors such as the large number of approvals, rising prevalence of cancer, rising demand for monoclonal antibodies personalized medicines, and the expansion of policies by payers to cover most immunotherapy drugs are driving the market growth.

Hospitals are the largest end-user segment of the immunotherapy drugs market.

On the basis of end users, the immunotherapy drugs market is segmented into hospitals, clinics, and other end users. The hospitals segment accounted for the largest share of the global immunotherapy drugs market, by end user, in 2019. Factors contributing to the large share and high growth of this segment include the rising spending by hospitals on immunotherapies, the prevalence of cancer and autoimmune diseases, and the availability of the necessary infrastructure and facilities.

Request Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=137717755

North America dominates the immunotherapy drugs market during the forecast period.

In 2019, North America accounted for the largest share of the immunotherapy drugs market, followed by Europe. The increasing prevalence of cancer, rising demand for quality diagnostics, the introduction of favorable reimbursement policies, and the implementation of favorable initiatives are some major factors driving the growth of the immunotherapy market in North America. However, the Asia Pacific region is expected to grow at the highest rate during the forecast period, owing to factors such as aggressive investments by key market players, increased government spending on healthcare, and rising disposable income of the population.

Key Market Players

The major players in the global immunotherapy drugs market are F. Hoffmann-La Roche Ltd. (UK), Pfizer Inc. (US), Merck Co (US), Novartis International AG (UK), Johnson Johnson (US), Sanofi (France), GlaxoSmithKline Plc (UK), Amgen Inc. (US), AbbVie Inc. (US), Boehringer Ingelheim (Germany), AstraZeneca (UK), and Immatics Biotechnologies (Germany), BioNTech SE, Genmab, Gilead Sciences, NBE Therapeutics, Teva Pharmaceuticals, Bayer, and Bristol-Myers Squibb.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=137717755

Browse Adjacent Market: 3D Bioprinting Market Research Reports Consulting

Related Reports:

Skin Health Foods Market / Dermatology Functional Foods Market by Indication (Skin Conditions, Anti-Aging, Anti-Allergy), Region (North America, Europe, Asia Pacific, Rest of the World), Regulatory Landscape, Pricing Analysis, COVID-19 Impact - Global Forecast to 2026

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their pain points around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 Micro Quadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: sales@marketsandmarkets.com

Visit Our Website: https://www.marketsandmarkets.com/

Content Source: https://www.marketsandmarkets.com/PressReleases/analytical-standards.asp

Comentarios